And even then, you can follow every “rule” and get ... of the FDA's approval this week, the move could help the company stand out from other brain chip interface companies. Neuralink's ...

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' INGREZZA drug to treat movement disorders associated with Huntington's disease, the company ...

WASHINGTON, April 8 (Reuters) - Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup ... No company has received final FDA approval to market a BCI brain implant.

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...

While Neuralink has not provided updates on its clinical trials, Synchron continues to advance in the brain-computer interface market, which has yet to see a company gain final FDA approval for a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the ...

The FDA granted accelerated approval to tovorafenib (Ojemda) to treat patients with relapsed or refractory BRAF -altered ...

ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with ...

X4 Pharmaceuticals (NASDAQ:XFOR) said the FDA has approved Xolremdi capsules, also known as mavorixafor, for the treatment of the rare condition WHIM syndrome in patients aged 12 and older.

The Swiss pharmaceutical company said Tuesday that the Food and Drug Administration has approved the therapy for the treatment of patients aged 12 and older with somatostatin receptor-positive ...

Day One Biopharmaceuticals' drug tovorafenib, or Ojemda, received accelerated approval from the U.S. Food and Drug Administration for patients with relapsed or refractory BRAF-altered pediatric ...